Review article: Prevention of non-steroidal anti-inflammatory drug gastrointestinal complications - Review and recommendations based on risk assessment

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 10, 2004, Pages 1051-1061

  Chan, F K L ^a   Graham, D Y ^b,c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIULCER AGENT; CELECOXIB; CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PIROXICAM; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; STEROID; STOMACH SECRETION INHIBITOR; WARFARIN;

ABDOMINAL CRAMP; AGING; ANALGESIA; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DUODENUM ULCER; FLUID RETENTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TRACT; GOUT; HEALTH CARE COST; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HYPERTENSION; INFECTION RISK; INFLAMMATORY DISEASE; INTESTINE PERFORATION; KIDNEY FAILURE; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STOMACH ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ASPIRIN; CYCLOOXYGENASE 2; DECISION MAKING; GASTROINTESTINAL DISEASES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MISOPROSTOL; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTON PUMPS; RISK ASSESSMENT; RISK FACTORS; STOMACH ULCER;

EID: 2542612880     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01935.x     Document Type: Review

References (57)

1. Singh G, Triadafilopoulus G. Epidemiology of NSAID-induced GI complications. J Rheumatol 1999; 26(Suppl. 26): 18-24.
2. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22.
3. Graham DY. Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding - Dr Graham replies [letter]. N Engl J Med 2003; 348: 2466.
4. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257-63.
5. Gabriel SE, Jaakkimainen L, Bombardier C. Risks for serious gastrointestinal complications related to the use of non-steroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115: 787-96.
6. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8.
7. Henry D, Lim LL, Rodriguez LAG, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-6.
8. Rodriguez LAG, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72.
9. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-9.
10. El-Serag HB, Graham DY, Richardson P, Inadomi JM. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis. Arch Intern Med 2002; 162: 2105-10.
11. Graham DY. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol 1996; 91: 2080-6.
12. LeLorier J. Patterns of prescription of nonsteroidal antiinflammatory drags and gastroprotective agents. J Rheumatol Suppl. 1995; 43: 26-7.
13. Graham DY. NSAID ulcers: prevalence and prevention. Mod Rheumatol 2000; 10: 2-7.
14. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82: 1153-8.
15. Graham DY. High-dose famotidine for prevention of NSAID ulcers? [editorial; comment]. Gastroenterology 1997; 112: 2143-5.
16. Sung JY, Lau JY, Chan FK, Graham DY. How often are endoscopic ulcers in NSAID trials diagnosed as actual ulcers by experienced endoscopists [Abstract]. Gastroenterology 2001; 120(Suppl. 1): A597.
17. Rostom A, Dube C, Wells G et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002; 4: CD002296.
18. Hudson N, Taha AS, Russell RI, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997; 112: 1817-22.
19. ten Wolde S, Dijkmans BA, Janssen M, Hermans J, Lamers CB. High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs. Aliment Pharmacol Ther 1996; 10: 347-51.
20. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs. N Engl J Med 1996; 334: 1435-9.
21. Simon TJ, Berger ML, Hoover ME, Stauffer LA, Berline RG. A dose ranging study of famotidine in prevention of gastroduodenal lesions associated with non-steroidal anti-inflammatory drugs (NSAIDs): results of a US multicenter trial [Abstract]. Am J Gastroenterol 1994; 89: 1644.
22. Ekstrom P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic Multicentre Study. Scand J Gastroenterol 1996; 31: 753-8.
23. Cullen D, Bardhan DK, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998; 12: 135-40.
24. Yeomans ND, Tulassay Z, Juhasz L, et al. Omeprazole compared with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 719-26.
25. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with non-steroidal antiinflammatory drugs. N Engl J Med 1998; 338: 727-34.
26. Ehsanullah RS, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988; 297: 1017-21.
27. Graham DY. Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users. Helicobacter 2002; 7: 1-8.
28. Janssen M, Dijkmans BA, Vandenbroucke JP, Biemond I, Lamers CB. Achlorhydria does not protect against benign upper gastrointestinal ulcers during NSAID use. Dig Dis Sci 1994; 39: 362-5.
29. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs. lansoprazole. Arch Intern Med 2002; 162: 169-75.
30. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 1921-8.
31. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999; 117: 776-83.
32. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000; 284: 1247-55.
33. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8.
34. Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002; 123: 1006-12.
35. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 2104-10.
36. Graham DY. Ulcer complications and their nonoperative treatment. In: Sleisenger, MH, Fordtran, JS, eds. Gastrointestinal Disease. Pathophysiology, Diagnosis, Management, 5th edn. Philadelphia: WB Saunders Co, 1993; 698-712.
37. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992; 116: 705-8.
38. Graham DY, Hepps KS, Ramirez FC, Lew GM. Treatment of H. pylori reduces the rate of rebleeding in complicated peptic ulcer disease. Scand J Gastroenterol 1993; 28: 939-42.
39. Labenz J, Borsch G. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion 1994; 55: 19-23.
40. Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 975-9.
41. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998; 352: 1016-21.
42. Bayer Pharmaceuticals. Facts About Aspirin. http://www.wonderdrug.com/ press/factsheets/aspirin fact sheet.pdf, accessed 28 July 2000.
43. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321: 1183-7.
44. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet 1991; 338: 1345-9.
45. Final Report on the Aspirin Component of the Ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321: 129-35.
46. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-62.
47. http://www.fda.gov/ohrms/dockets/ac/03/transcripts/4012T1. htm, accessed 8 December 2003.
48. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827-30.
49. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the clopidogrel in unstable angina to prevent recurrent events (CURE) study. Circulation 2003; 108: 1682-7.
50. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 124: 288-92.
51. Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003; 108: 1191-5.
52. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17.
53. Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, Morelli A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003; 124: 600-7.
54. Fiorucci S, Del Soldato P. NO-aspirin: mechanism of action and gastrointestinal safety. Dig Liver Dis 2003; 35(Suppl. 2): S9-19.
55. Ng FH, Wong SY, Chang CM, et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther 2003; 18: 443-9.
56. Schwartz JI, Bugianesi KJ, Ebel DL, et al. The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin. Clin Pharmacol Ther 2000; 68: 626-36.
57. Karim A, Tolbert D, Piergies A, et al. Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects. J Clin Pharmacol 2000; 40: 655-63.